<DOC>
	<DOCNO>NCT02849262</DOCNO>
	<brief_summary>The purpose study ass pharmacodynamics , safety efficacy omiganan patient external genital wart .</brief_summary>
	<brief_title>Pharmacodynamics , Safety Efficacy Topical Omiganan Patients With External Genital Warts</brief_title>
	<detailed_description />
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . Healthy male female subject â‰¥ 18 year age , external genital wart . The health status verify absence evidence clinical significant active uncontrolled chronic disease genital wart follow detailed medical history complete physical examination include vital sign 12lead ECG . In case uncertain questionable result , test perform screen may repeat randomization confirm eligibility judge clinically irrelevant healthy subject . 2 . Clinically diagnosed biopsy confirm external genital wart . Subject least 3 external genital wart . 3 . Willing give write informed consent willing able comply study protocol . Eligible subject must meet none follow exclusion criterion screen : 1 . Clinically significant abnormality , judge Investigator , laboratory test result include haematology , blood chemistry panel , virology urinalysis . In case uncertain questionable result , test perform screen may repeat randomization confirm eligibility judge clinically irrelevant healthy subject . 2 . Current clinically significant skin condition anogenital area ( e.g . atopic dermatitis , lichen sclerosus , lichen planus psoriasis ) . 3 . Pregnant , breast feeding try conceive . 4 . Participation investigational drug device study within 3 month prior screen 4 time year . 5 . Loss donation blood 500 mL within three month ( male ) four month ( female ) prior screen . 6 . Use active treatment ( i.e . cryotherapy , laser therapy , topical medication and/or surgical treatment ) genital wart within 28 day prior first study drug administration . 7 . Immunosuppressed patient , immunodeficiency ( primary secondary , like HIV ) receive immunosuppressive therapy ( i.e . Transplant patient ) . 8 . Males Females receive vaccination Gardasil Cervarix . 9 . Any ( medical ) condition would , opinion Investigator , potentially compromise safety compliance patient may preclude patient 's successful completion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>